Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 Infections
CARLSBAD, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company…
Why Compliance Still Needs Human Judgment in the Age of AI
Make Named Best AI Automation Platform for 2026